cd19-tricar-silk
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2019 (NCT03790891)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03910842 | Early Phase 1 (Phase 1) | May 15, 2019 | Central South University, Timmune Biotech Inc. |
| NCT03790891 | Early Phase 1 (Phase 1) | Jan 5, 2019 | Hainan People's Hospital, Timmune Biotech Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Timmune Biotech Inc. | For profit | 2 | 2 | 1 | 2019 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Hainan People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1